Inhalation Sciences ships first fully commercialized DissolvIt[®][ ]module
In a historic move ISAB has shipped its first fully commercialized DissolvIt in vitro module. The original Purchase Order for the shipment, made in September 2018, was worth 65.000 euros. The shipment is to the central Swiss labs of a global ISAB customer. DissolvIt has delivered landmark Contract Research data for clients throughout its development and is in high demand for its unique IVIVC capabilities.
DissolvIt has long been in demand—and now it’s being delivered. The fully commercialized iteration is being shipped to a client’s labs in Switzerland, following ten years of development where the module has been tested in many challenging contract research (CRO) projects, delivering detailed in vitro data that correlates closely to in vivo findings.
CEO Manoush Masarrat: “DissolvIt has been seen by many in the industry as the first tool that can seriously show In Vitro-In Vivo correlation (IVIVC). That makes it a powerful screening tool with enormous strategic value. Precise, predictive, preclinical IVIVC data means drug developers can put credible strategies in place for formulation before crucial time and money has been spent in clinic—reducing risk and development costs and increasing precision and speed of development.”
DissolvIt will also create a new revenue stream for ISAB, through the sale of the tool’s disposable Dissolution Chambers. These circular test cartridges are inserted into the tool for dissolution testing. New systems include an initial package of 12 disposable units, with new packages available quickly on request.
Every single component in the final commercial release of DissolvIt is precision-engineered to exacting standards, to eliminate any risk of deviation. Key features such as the high-resolution optical microscopy camera, which shows particles dissolving in real-time on the simulated lung lining, have been fully optimized. DissolvIt’s easy-to-use software package automatically activates and measures every stage of the dissolution, again ensuring exacting precision and eliminating human interference.
Manoush Masarrat: "I’d really like to thank the entire ISAB team for their fantastic work in reaching full commercialization. The successful launch of a tool as unique and innovative as DissolvIt underlines the huge skills and dedication of the team. The innovation across disciplines has been exceptional. From the years of rigorous, challenging, highly creative CRO work in the lab, to the sophisticated operating and data software, to the commercial conceptualizing, labelling, manufacture and packaging—all of these took outstanding teamwork and commitment—and I believe DissolvIt will reward us and our customers richly.
“Let’s not forget—this shipment, and the original order, came out of a successful research collaboration. We’ve already delivered exceptional CRO results using DissolvIt, and we know that the data generated had a big impact on our customers. DissolvIt has already received advanced orders and earned enormous respect. All thanks to our team. The volume and precision of data it delivers should prove to customers that IVIVC data really are here and now—and that whatever their challenge—they can solve it with DissolvIt.”
DissolvIt key benefits and features:
- Ranks substances according to solubility
- Monitors absorption as well as dissolution
- Identifies successful, effective Drug Candidates early on
- Delivers exceptionally detailed data incl. Cmax and Tmax curves
- Optical microscopy shows real-time dissolution of particles
- Customizable, programmable Fraction Collector for flexible sampling
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB (publ) for publication on March 16, 2020.